Many commentators have compared the rise of GLP-1 obesity drugs to Viagra, pointing to their rapid social acceptance and huge demand. Indeed, Viagra was a cultural breakthrough. It turned a private problem into something openly discussed and treated – creating demand. Its success owed as much to social acceptance as to clinical effectiveness.
Lipitor was different. Pfizer was the fourth – not first – entrant in the statin class. Its success came from becoming embedded in clinical guidelines, routine care, and national reimbursement systems. Growth followed system adoption rather than consumer demand.
GLP-1 therapies share far more with Lipitor's commercial profile than Viagra's. They sit at the intersection of chronic disease management, state reimbursement, complex supply chains, and eventual genericization. The structural dynamics – and the structural risks – are closely analogous. And the Lipitor story in Europe is a warning that has not yet been widely told.
The Norway case: a warning in the data
Between 2004 and 2007, Lipitor held full patent protection in Norway. Pfizer owned the patent and managed direct imports. However, a detailed analysis of approximately 1.4 million prescription transactions across 170,000 individuals revealed a striking pattern: Pfizer was systematically losing sales not to a competitor drug, but to parallel imports of its own molecule.
Norway's pharmacy market is highly concentrated. Three chains – Apotek 1, Boots, and Vitus – control 87 percent of all pharmacies and are vertically integrated with their upstream wholesalers. Their preference for parallel imports was not medical but financial.
Within the European Economic Area, the free movement of goods and the exhaustion of intellectual property rights make parallel trade in medicines entirely legal. Atorvastatin, manufactured by Pfizer and sold in Spain, France, Greece, and Italy at prices shaped by those countries' regulatory frameworks, could be legally acquired by specialist parallel importers, repackaged to meet Norwegian labelling requirements, and sold into the Norwegian market at a wholesale price below what Pfizer itself charged – while still offering the pharmacy chain a superior margin.
From 2004 to 2006, parallel imports constituted approximately 90 percent of the 80mg atorvastatin segment in Norway. Pharmacy chains earned a 4–16 percent higher margin on parallel imported stock than on Pfizer's direct supply – and predictably, they directed patients towards it. This isn’t unusual practice; it is rational commercial behavior within a structurally distorted system.
The headline figure is the counterfactual: econometric modelling by Dubois and Sæthre (2020) estimates that Pfizer's Norwegian Lipitor sales would have been more than double – +104 percent – in the absence of parallel trade (revenue data sourced from Pfizer/Statista). Crucially, this was during the patent period, not after loss of exclusivity.
The regulatory architecture that makes this possible
This is not a Pfizer-specific failure; it reflects the structure of the European Economic Area. Cross-country pharmaceutical price differentials within Europe can reach 300 percent, arising from heterogeneous national regulatory frameworks: reference pricing, statutory margins, reimbursement rules, and the bargaining power of national health authorities. Norway sets its price caps annually against an average of the three lowest retail prices across nine comparator countries. These conditions create persistent price gaps – and price gaps create arbitrage opportunity.
The legal framework is unambiguous. Articles 34 and 35 of the Treaty on the Functioning of the European Union guarantee free movement of goods. The Court of Justice of the European Communities established exhaustion of intellectual property rights within the single market in the late 1960s. Once a drug is sold into any EEA market, the manufacturer cannot prevent its onward movement. The parallel trader needs only a sales licence from the national medicines agency – regulated but accessible – and the commercial logic does the rest.
What Ghemawat's adaptation, aggregation, and arbitrage (AAA) framework (see sidebar below) illuminates is the adaptation-aggregation-arbitrage tension that plays out across multinational pharmaceutical strategies. Pfizer's direct marketing of atorvastatin in Norway was undermined by its inability to close the arbitrage channel – because the legal and regulatory architecture actively preserved it.
Ghemawat’s AAA Framework Applied to Pharma Franchise Defence
Adaptation
Local pricing responsiveness. But price reductions in one market ripple through reference pricing networks across the EU – a race to the bottom that erodes margins system-wide.
Aggregation
Scale economies through standardization. Optimal for manufacturing cost – but creates the uniform product that parallel traders exploit across price-differentiated national markets.
Arbitrage
The threat, not the opportunity. Crossmarket price exploitation by intermediaries. For GLP-1 innovators, this is the channel requiring closure – not leverage.
What this means for GLP-1s
Novo Nordisk and Eli Lilly do not have a demand problem. GLP-1 therapies target a condition affecting more than a billion people worldwide, and evidence of their wider health benefits continues to grow. Major trials are linking these drugs to improvements in cardiovascular outcomes, metabolic disease, and even musculoskeletal health. For governments and healthcare payers, the interest is obvious: if these treatments deliver on their promise, the potential savings in downstream healthcare costs could be substantial.
But the strategic challenge here is structural, and it is already becoming visible.
Compounding pharmacies in the United States exploited regulatory gaps during the semaglutide shortage to produce and sell unlicensed versions at significantly lower prices – a form of domestic parallel trade that regulators are only now beginning to address. In Europe, the established parallel trade infrastructure is well positioned to exploit price differences between national markets as reimbursement negotiations conclude at different levels. Novo’s IP strategy has already been tested and found wanting in some jurisdictions.
Loss of exclusivity, while still years away, will also arrive. When it does, the question will be what kind of franchise equity has been built – in ecosystems, outcomes data, and payer relationships – and whether GLP-1s follow Humira’s post-biosimilar resilience or Lipitor’s dramatic cliff.
Three strategic imperatives
The Lipitor case highlights several practical lessons for companies building GLP-1 franchises today. Three in particular stand out.
Build a defensible ecosystem at launch
Drugs alone are vulnerable. Integrated ecosystems – combining connected devices, diagnostics, digital monitoring, clinical decision support, and real-world outcomes tracking – create switching costs that outlive patents. The precedent is Novo's own insulin portfolio, which retained patient loyalty well beyond patent expiry through device and service integration. GLP-1s provide a more compelling opportunity: the clinical monitoring required to manage weight loss trajectories, titration, and complication screening creates natural digital touchpoints that a connected care ecosystem can own. If the innovator does not build this, the pharmacy chain will – and the economics will follow the same pattern as Lipitor in Norway.
Control the economics of the vertical chain
The Norway case provides a specific, testable lesson: parallel import margins were consistently higher than direct import margins because parallel import wholesale prices were consistently lower. The pharmacy chains' incentive to direct patients to parallel imports was purely economic. Pfizer's optimal countermove would have been to reduce its Norwegian wholesale price sufficiently to erode the parallel importers' margin advantage – a strategy consistent with EEA competition rules and potentially accretive to total profit given the +104% counterfactual uplift. For GLP-1 innovators, the equivalent question is: at what point do compounders and parallel traders become margin-accretive to intermediaries? And how is that channel closed before it reaches Norwegian statin scale?
Solve the payer paradox through outcomes architecture
The tension between affordable population-level access and sustainable innovation economics is real and will not resolve itself. But the strongest defense against both pricing pressure and intermediary arbitrage is robust outcomes evidence that anchors reimbursement to demonstrable value rather than volume. Outcomes-based contracts, real-world evidence programs, and population health partnerships shift the conversation from price per unit to cost per avoided hospitalization, per prevented cardiac event, per quality-adjusted life year gained. This reframes the payer relationship and creates a data moat that generic entrants and parallel traders cannot easily replicate. It is also, frankly, what health systems need – and what the NHS £3,000 GP top-up scheme emphatically does not provide.
Strategy will decide who captures the value
GLP-1s may genuinely change the face of global health – and the clinical evidence increasingly suggests they will. But whether the innovators capture that value, or whether it is redistributed through the same structural channels that cost Pfizer more than half its Norwegian statin revenues while on patent, will depend less on the molecule and far more on how the franchise is defended.